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evaluation in non-small cell lung cancer
patients evaluated with F-18-FDG PET/CT
early in the course of chemo-radiotherapy
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Abstract
Background: The purpose of this study is to determine whether a qualitative approach or a semi-quantitative
approach provides the most robust method for early response evaluation with 2′-deoxy-2′-[18F]fluoro-D-glucose
(F-18-FDG) positron emission tomography combined with whole body computed tomography (PET/CT) in non-
small cell lung cancer (NSCLC).
In this study eight Nuclear Medicine consultants analyzed F-18-FDG PET/CT scans from 35 patients with locally
advanced NSCLC. Scans were performed at baseline and after 2 cycles of chemotherapy. Each observer used two
different methods for evaluation: (1) PET response criteria in solid tumors (PERCIST) 1.0 and (2) a qualitative
approach. Both methods allocate patients into one of four response categories (complete and partial metabolic
response (CMR and PMR) and stable and progressive metabolic disease (SMD and PMD)). The inter-observer
agreement was evaluated using Fleiss’ kappa for multiple raters, Cohens kappa for comparison of the two methods,
and intraclass correlation coefficients (ICC) for comparison of lean body mass corrected standardized uptake value
(SUL) peak measurements.
Results: The agreement between observers when determining the percentage change in SULpeak was “almost
perfect”, with ICC = 0.959. There was a strong agreement among observers allocating patients to the different
response categories with a Fleiss kappa of 0.76 (0.71–0.81). In 22 of the 35 patients, complete agreement was
observed with PERCIST 1.0. The agreement was lower when using the qualitative method, moderate, having a Fleiss
kappa of 0.60 (0.55–0.64). Complete agreement was achieved in only 10 of the 35 patients. The difference between
the two methods was statistically significant (p < 0.005) (chi-squared).
Comparing the two methods for each individual observer showed Cohen’s kappa values ranging from 0.64 to 0.79,
translating into a strong agreement between the two methods.
Conclusions: PERCIST 1.0 provides a higher overall agreement between observers than the qualitative approach in
categorizing early treatment response in NSCLC patients. The inter-observer agreement is in fact strong when using
PERCIST 1.0 even when the level of instruction is purposely kept to a minimum in order to mimic the everyday
situation. The variability is largely owing to the subjective elements of the method.
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Background
A vast palette of new types of anti-cancer agents, includ-
ing more or less specific targeted treatments, has be-
come available to many cancer patients including those
with non-small cell lung cancer (NSCLC).
Unfortunately, not all patients respond to all treat-
ments, and the matter of selecting the optimal treatment
for each patient is a key element in minimizing the num-
ber of fruitless treatments with unnecessary and harmful
side effects, as well as improving survival. In addition, an
optimal treatment selection will contribute to keeping
exploding health costs down—a pending problem, espe-
cially in medical oncology.
Early information on treatment effectiveness will be of
great importance in personalized treatment planning.
Consequently, this accentuates the urgency of identifying
a robust method for early response evaluation. In the
past, we have relied on measuring changes in tumor size,
initially from chest X-rays and presently in CT images,
following various classifications and recommendations:
The World Health Organization (WHO) classification
from 1979 [1], followed by Response Evaluation Criteria
In Solid Tumors (RECIST) from 2000 [2] updated in
2009 to RECIST 1.1 [3]. Two major issues are of great
importance when using these measurements: (1) tumor
shrinkage takes time; a major limitation for early re-
sponse evaluation using CT and (2) accurate change in
size measurements can be very observer dependent. Al-
though some studies have shown good inter-observer
agreement, especially when evaluating metastasis [4–6],
others (mostly primary tumor studies) have demon-
strated rather poor agreement with a resulting high risk
of misclassification [7–9]. In clinical trials, it is possible
to overcome this observer dependency by limiting the
number of radiologists performing the measurements,
but this introduces a problem when comparing studies,
and especially when interpreting patient data outside of
the clinical trial setting.
Positron emission tomography (PET) using the tracer
2′-deoxy-2′-[18F]fluoro-D-glucose (F-18-FDG) combined
with whole body computed tomography (F-18-FDG
PET/CT), is already a well-established method for rou-
tine staging of NSCLC patients [10, 11]. Parallel to the
increase in available anti-cancer pharmaceuticals, PET/
CT scanners are now available in most centers treating
NSCLC patients.
In spite of the lack of agreement on which method to
use for quantifying the change in FDG-uptake, many
studies over the past 10–15 years agree that a change in
uptake during treatment contains valuable information
regarding whether a patient will respond favorably to a
given treatment. The metabolic response, measured as
an early change in FDG-uptake, has been shown to pre-
dict both the histological response [12–18] and the post
treatment evaluated response [19–21] to both chemo-
and radiotherapy [22] in NSCLC patients.
In the principle, there are two different approaches to
evaluate a change in FDG-uptake in non-dynamic,
standard protocol F-18-FDG PET/CT scans: qualitative
evaluation, which visually graduates the change as
suggested by Hicks et al. [10], and a semi-quantitative
approach calculating the percentage change in standard-
ized uptake value (SUV). In 2009, Wahl et al. [23] pub-
lished their suggestion for PET Response Criteria In
Solid Tumors: PERCIST 1.0, thereby taking up the chal-
lenge on lack of uniformity.
This study aims to evaluate the inter-observer agree-
ment among F-18-FDG PET/CT evaluators at our insti-
tution, using both PERCIST 1.0 response evaluation
criteria [23] and the qualitative method of visual evalu-
ation as defined by Hicks et al. [10]. Furthermore, we
explore whether using the semi-quantitative method of
PERCIST 1.0, as opposed to the more subjective quali-




The F-18-FDG PET/CT scans of the first 35 consecutive
patients with pathologically proven stage IIB-IIIB
(American Joint Committee on Cancer Staging), in-
operable NSCLC enrolled in a national phase II trial
were evaluated. The Danish National Ethical Board ap-
proved the trial (S209-0012). Patients were included and
treated between May 2009 and March 2012 at one of
two centers: Aarhus University Hospital and Odense
University hospital. Written informed consent was ob-
tained from all patients.
Induction chemotherapy consisted of Carboplatin
(given as intravenous perfusion day 1) combined with
Vinorelbine (60 mg/m2 days 1 and 8 as tablets delivered
as 21-day cycles).
Imaging
All patients had an F-18-FDG PET/CT scan performed
at diagnosis (baseline) and after 2 cycles of induction
chemotherapy (follow-up), prior to the radiotherapy
course. The baseline F-18-FDG PET/CT scan and the
follow-up F-18-FDG PET/CT scan were performed on
the same type of scanner, at the same center. Nineteen
of the 35 patient scans were performed at the PET-
Centre, Aarhus University Hospital, using one of three
integrated PET/CT scanners (Siemens Biograph True-
Point 40, Siemens Healthcare GMbH, Erlangen,
Germany). A low-dose CT scan (50 mA, 120 kV) was
performed for attenuation correction purposes and to
determine anatomical localization. Following the scan,
the images were reconstructed using the system’s
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AW-OSEM algorithm (21 subsets and 3 iterations) in
a matrix of 168 × 168 (4.07 mm/pixel) and post-
filtered with a 3.0-mm FWHM Gaussian. The patients
were injected intravenously with F-18-FDG (5 MBq
pr. kg +/− 10 % (min. 150 MBq, max. 700 MBq) after
a fasting period of at least 6 h. The scans were ob-
tained approximately 1 h after F-18-FDG injection.
The remaining 16 patient scans were performed at the
PET-Centre, Odense University Hospital, where they
were performed with either a 16-slice or 64-slice hybrid
PET/CT scanner (GE Discovery 690, GE Discovery VCT,
GE Discovery RX, or GE discovery STE, GE Healthcare,
Broendby, Denmark) with scan length including the
skull to the upper thighs. Low-dose CT scans without
intravenous contrast media were performed using a
standardized CT protocol, reconstructed with filtered
back projection and a standard GE filter with a field
of view of 50 cm (slice thickness of 3.8 mm Smart mA
30–110 mA, 140 kV, noise index 25.0, 0.8 s/rotation.
Emission images were acquired in 3-dimensional mode
(2.5 min per bed position). Data were reconstructed with
a 70 cm field of view, matrix size 128 × 128 or 256 × 256,
slice thickness of 3.75 mm using iterative ordered-subset
expectation maximization. The CT scan was also used
for attenuation correction using a standard, vendor-
provided, filter for this purpose.
Bedside plasma glucose concentrations were measured
in all patients prior to injection of F-18-FDG using the
“Precision Xceed” monitor (Abbott A/S, Abbot Diabetes
Care, Copenhagen, Denmark).
Evaluation
Eight observers, with varying levels of experience in
F-18-FDG-PET/CT evaluation, were asked to participate
in this study. Observers A, D, and E had little experience
(one junior and two specialists, but not with FDG), ob-
servers C and G both had more than 3 years of experience
with a special interest in response evaluation, and ob-
servers B, F, and H had 1–2 years of experience with
FDG-PET evaluation. Observers were blinded to clinical
information; additional diagnostic information including
CT scans at any time point and clinical outcome informa-
tion. All observers received written information on the
qualitative method of visual evaluation of response as de-
fined by Hicks et al. [10], and of the PERCIST 1.0 re-
sponse evaluation criteria [23].
F-18-FDG-PET/CT scans at baseline and at follow-up
after 2 cycles of induction chemotherapy were evaluated;
firstly, according to the qualitative method where the re-
sponse categories were recorded together with any com-
ments on difficulties (e.g., whether a new focus was
suspected to be malignant or benign, atelectases, etc,).
Secondly, all observers were asked to evaluate the same
patients using PERCIST 1.0, including SUVpeak values
corrected for lean body mass (SULpeak). All observers
reported SULmean liver and SD for a standard 3 cm
ROI in the right lobe at baseline. The minimum level for
evaluation as defined by PERCIST 1.0 (1.5 ×mean liver
SUL + 2SD) was automatically calculated in the report
file. All observers reported the highest observed SUL-
peak value in the most intense tumor lesion at baseline
and at follow-up, not necessarily the same lesion; the
percentage change was automatically calculated in order
to rule out calculation errors. They also reported the
final PERCIST response categories for each patient and
comments in case of difficulties. A consensus classifica-
tion was made for comparison, choosing the response
category the majority of observers used, or in case of an
equal split (three difficult cases in the qualitative ana-
lysis), the comments on difficulties reported by the ob-
servers were used to determine the category for
consensus and confirmed by reevaluation by one experi-
enced observer. The criteria for categorizing response by
the two methods are summarized in Table 1.
Statistical analysis
All statistics were calculated using www.statstodo.com.
The inter-observer agreement in reporting response cat-
egories was evaluated using weighted Fleiss’ kappa for
multiple raters, for both the qualitative method and
Table 1 A summary of the definitions of measurability and response categories
Visual evaluation PERCIST 1.0
Measurable lesions FDG avid above background SUL peak at least 1.5 times SULmean liver + 2 SD
CMR* FDG avid lesions revert to background of normal
tissue in which they are located
Disappearance of all measurable lesion to background
blood-pool levels
PMR* Significant reduction in intensity of tumor
metabolic activity
Reductions of min. 30 % in target SULpeak, with an absolute
drop of at least 0.8. No new lesions
SMD* No visible change in metabolic activity of tumors Not CMR, PMR, or PMD
PMD* Increase in intensity or extent of tumor metabolic
activity or new lesions typical for cancer
More than 30 % increase in target SULpeak, with an absolute
increase of at least 0.8. Or visible increase in extent without
drop in SULpeak. Or appearance of new FDG avid lesions
typical of cancer, not related to treatment or infection
* Abbreviations: CMR = Complete Metabolic Response, PMR = Partial Metabolic Response, SMD = Stabile Metabolic Disease and PMD = Progressive
Metabolic Disease
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PERCIST 1.0., Cohen’s kappa was used for pair-wise
comparison of observers and for evaluating agreement
between the two methods for each observer. All kappa
values are reported as linear weighted kappa (95 % confi-
dence interval). Kappa values were interpreted according
to Landis and Koch [24] as summarized in Table 2. Dif-
ferences between the two methods were tested using the
chi-squared test. Intraclass correlation coefficients (ICC)
were used to evaluate the correlation between different
observers in the case of SULpeak and liver SUL mea-
surements, interpreted using a similar scale as for kappa
values (Table 2).
Results
All observers evaluated all 35 patients, assigning each
patient a response category (Table 1). All observers con-
sidered all patients evaluable. Although all observers
were informed to report SULpeak values for background
when the response was considered complete, a SULpeak
value of 0.0 was reported at follow-up in nine cases. Six
of these were for a single patient showing complete re-
sponse. In spite of this, the ICC for follow-up SULpeak
was 0.9537, the ICC for baseline SUL peak was 0.9643,
and the ICC for percentage change in SULpeak was
0.9585, all translating into almost perfect agreement, as
defined in Table 2. The SULpeak values for each patient
at baseline, follow-up, and percentage change in SUL
peak between baseline and follow-up are presented in
Figs. 1, 2, and 3.
Using PERCIST 1.0 for categorizing response, there
was complete agreement between all 8 observers in 22
of the 35 patients; the Fleiss kappa was 0.76 (0.71–0.81)
in the strong agreement category (Fig. 4). Of the 13
cases of disagreement, 10 were attributed to the subject-
ive evaluation of complete response, new foci evaluated
as malignant and visual growth of the tumor. Two of the
remaining three were attributed to a numerical rounding
off uncertainty and the last one to an unexplained devi-
ating SULpeak value at baseline for one observer. When
using the qualitative method, there was complete agree-
ment among all 8 observers in only 10 of the 35 patients
(statistically significant difference; p < 0.005), and the
Fleiss kappa was significantly lower 0.60 (0.55–0.64), in
the moderate agreement category. Both single level of
difference (SMD/PMR or PMR/CMR) and multilevel dif-
ference in all cases SMD/PMD were lower using PER-
CIST as compared to visual evaluation. A comparison of
the levels of agreement is presented in Fig. 5. The multi-
level agreement is considered clinically relevant in all
cases since progression during chemotherapy is consid-
ered to be a contraindication to continuing curatively
intended chemo-radiotherapy, also single level agree-
ment involving SMD/PMD differences is equally import-
ant. Evaluating qualitatively in 15 patients, we found
these clinically important differences and in 9 patients
using PERCIST. In most cases, it was only one observer
deviating from the rest. A summary of these cases is pre-
sented in Table 3.
Focusing on the cases with more than one observer
disagreeing, it is mainly owing to “new focus” found by
some observers. An example is presented in Fig. 5.
A comparison of observer interpretation, “one-on-one”,
was also performed for each method in supplement to the
Table 2 Interpretation of kappa values and intraclass correlation
coefficients (ICC) based on Landis and Koch [24]





0.81–1.00 Near complete agreement
Fig. 1 SULpeak values at baseline for all eight observers (A–H). Note:
where agreement is complete all eight observations are stacked
Fig. 2 SULpeak values at follow-up for all eight observers (A–H).
Note: where agreement is complete all eight observations
are stacked
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multiple reader comparison. The pair-wise comparison
kappa values (presented in Table 4) for PERCIST 1.0
(range 0.60–0.88) corresponded to strong agreement in 19
of the 28 compared pairs and near complete agreement
for 9 compared pairs. Comparing each observer with the
consensus evaluation, the kappa values (range 0.70–0.95)
correspond to four observers in “near complete agree-
ment” and four in “strong agreement” with the consensus.
Interestingly, observer G (an experienced observer) had
the lowest kappa values. In contrast, the qualitative evalu-
ation of pair-wise comparison kappa values (range 0.50–
0.76) corresponded to 8 pairs with moderate agreement
and 20 pairs with strong agreement (presented in Table 5).
Using this method, no observer-pair reached near
complete agreement. Though compared with the consen-
sus, the kappa values (range 0.66–0.90) correspond to six
in strong agreement and two in near complete agreement
with the consensus. The level of disagreement was not
correlated to the level of experience. The observers’ agree-
ment with “consensus” for both methods is presented in
Fig. 6.
There was a strong agreement for all 8 observers when
comparing PERCIST 1.0 and qualitative evaluation for
each observer (kappa values ranged between 0.64 and
0.79) (Table 6).
The mean liver SUL was reported at baseline by all ob-
servers and showed only moderate agreement with an
ICC of 0.58, and the corresponding minimum value for
SULpeak for evaluation also only showed moderate
agreement (ICC of 0.52),
Discussion
The main finding of this study is that PERCIST 1.0 pro-
vides a higher overall agreement between observers than
when using the qualitative approach in categorizing early
treatment response in NSCLC patients with FDG-PET/
CT.
There has previously been some investigation into the
inter-observer variability of using F-18-FDG PET/CT for
staging and recurrence evaluation in various types of
cancers; some using qualitative evaluation [25–28] with
generally only moderate agreement among observers,
and some using SUV-based evaluation [5, 29–31] which
demonstrate better (mostly near perfect) agreement
among observers. To our knowledge, only two previous
studies have evaluated the inter-observer variability for
response evaluation; Jacene et al. [8] and Benz et al. [32]
for sarcoma and lung cancer patients, respectively, both
using a semi-quantitative approach and demonstrating
almost perfect agreement among observers.
Since SUV has been established as a parameter with
high reproducibility for pre-therapeutic evaluation in
various cancer types, including NSCLC [33–36], it is im-
portant to evaluate the observer’s contribution to the
overall variation.
This study was designed to provide additional infor-
mation to the previous studies on inter-observer vari-
ability, especially in the response evaluation setting, and
to test the hypothesis, which the more subjective, visual
approach to interpretation will have a larger dependency
on the individual observer than the more objective
method: PERCIST 1.0. We deliberately chose to provide
Fig. 3 SULpeak percentage change between baseline and follow-up
for all eight observers (A–H). Note: where agreement is complete all
eight observations are stacked. The horizontal lines represent the
30 % change levels used for discrimination between response
categories according to PERCIST 1.0. The arrows mark three patient
in whom a discrepancy results in different categorization. Red arrow:
A misclassification of possible clinical importance where G reported
PMD (30.8 % increase in SULpeak) and the other observers reported
SMD (28.6 %). The two black arrows: E reports SMD (13.6 % SULpeak
change) the others reported PMR (43 % change) and an example
where H report SMD (14.4 % decrease in SULpeak) and the other
observers report PMR (69.9 % decrease)
Fig. 4 Agreement among eight observers. Red is “multiple level
disagreement” defined as more than one response category
difference, i.e., some observers reported progressive disease and
some reported partial metabolic response. Yellow is “single level
disagreement” defined as only one response category difference for
one or more observers. Green is full agreement among all observers
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Fig. 5 A typical case of disagreement between observers. a is the baseline and b is follow-up. On the bottom, one of the foci with uptake on
follow-up is presented. In general, all observers found that a decrease in FDG-uptake was seen on follow-up (b), but three observers found that
new areas with high FDG-uptake represented new malignant lesions (PMD) and five observers evaluated PMR, indicating the foci most likely to
be benign. All observers reported a 51 % SULpeak decrease
Table 3 A summary of cases with disagreement in response categories for qualitative and PERCIST evaluation with a possible
clinical consequence
Qualitative evaluation PERCIST evaluation
Case Obs. Categories Cons. Reason for PMD Obs. Categories Cons.
5 1 SMD/PMD SMD Increased uptake 0
6 1 SMD/PMD SMD Increased uptake 0
7 1 SMD/PMD SMD NA 0
8 2 PMR/PMD PMR New focus 3 PMR-PMD PMR
14 5 PMR-PMD PMD New focus 3 PMR/PMD PMR
16 2 SMD/PMD PMD Increased uptake 1 SMD/PMD SMD
20 1 SMD/PMD PMD New focus 3 SMD/PMD PMD
21 1 SMD/PMD SMD New focus 1 SMD/PMD SMD
28 1 SMD/PMD PMD Increased size 1 SMD/PMD SMD
30 3 PMR/PMD PMR New focus 4 PMR/PMD PMR
31 1 SMD/PMD SMD Increased uptake 0
32 1 PMR/PMD PMR New focus 0
33 4 SMD/PMD SMD Increased uptake 0
34 1 SMD/PMD PMD Increased size 1 SMD/PMD SMD
35 2 SMD/PMD PMD New focus 3 SMD/PMD PMD
Obs. is number of observers disagreeing with consensus (Cons.)
Cases with more than one observer disagreeing are considered most important
Fledelius et al. EJNMMI Research  (2016) 6:71 Page 6 of 10
all evaluators with rather sparse information so as to
mimic the everyday clinical situation; the aim being to
evaluate actual agreement as it would present when
introducing the methods into routine evaluations. Meas-
uring SULpeak is incorporated in the PERCIST method,
since it has been shown to be a more reproducible par-
ameter than the more frequently used SUVmax [35, 37].
Furthermore, SULpeak has recently been shown to be
independent of acquisition time [38], but is potentially
slightly more observer dependent than SUVmax, espe-
cially in low uptake tumors.
We found that there was an almost perfect agreement
among eight observers when reporting SULpeak values
for all baseline values, follow-up values and percentage
changes. The ICC’s for SULpeak correspond well with
most other studies [8, 29–31]. We did not achieve
complete agreement, which also has been demonstrated
for methods using SUVmax in sarcoma patients [32]
and pulmonary nodules [5] previously. This is mostly ex-
plained by the reporting of SULpeak = 0.0 when a
complete response was observed at follow-up by some
observers, and in some instances reporting the wrong
SUV (corrected for body weight instead of LBM, as this
was the software default setting).
We report a statistically significant, higher rate of total
agreement among observers using PERCIST 1.0 as com-
pared to the qualitative method. Both methods however,
show a strong agreement among observers. To our
knowledge no other studies have made this direct com-
parison. A few studies have shown, that when using
qualitative, visual approaches to staging various cancers,
the inter-observer agreement is moderate in most cases
[25, 26, 28, 37, 39], even the well established Deauville
criteria for lymphoma evaluation was shown in a study
by Itti et al in 114 diffuse large B-cell lymphoma patients
to have only moderate agreement among experienced
observers [40].
Clearly, it is the more subjective parts of the PERCIST
1.0 that contribute most to the disagreement among
evaluators. This was indicated by the almost perfect cor-
relation between SULpeak values and by the observers’
individual added comments on new foci, tumor growth,
and inclusion of atelectases for the 13 patients, where
disagreement was found, all which helped highlight this
disagreement. The potentially important discrepancies
was mainly owing to new FDG avid foci, and whether or
not they were to be considered malignant, stressing the
importance of confirming the findings with biopsies.
Table 4 Cohen’s linear weighted kappa values for pair-wise comparison of observers for PERCIST 1.0
Observer A B C D E F G H
B 0.74 (0.54–0.94)
C 0.88 (0.75–1.01) 0.85 (0.67–1.02)
D 0.72 (0.48–0.96) 0.69 (0.43–0.96) 0.83 (0.61–1.06)
E 0.70 (0.47–0.93) 0.67 (0.42–0.93) 0.82 (0.62–1.03) 0.82 (0.62–1.03)
F 0.83 (0.64–1.03) 0.72 (0.47–0.96) 0.85 (0.68–1.06) 0.87 (0.68–1.06) 0.86 (0.70–1.01)
G 0.60 (0.32–0.88) 0.65 (0.40–0.90) 0.63 (0.33–0.92) 0.79 (0.59–1.00) 0.69 (0.42–0.95) 0.73 (0.48–0.99)
H 0.63 (0.38–0.87) 0.67 (0.46–0.88) 0.64 (0.40–0.90) 0.73 (0.52–0.94) 0.71 (0.49–0.93) 0.67 (0.45–0.90) 0.77 (0.59–0.94)
Cons. 0.80 (0.60–1.00) 0.76 (0.53–0.99) 0.92 (0.75–1.08) 0.92 (0.75–1.08) 0.91 (0.71–1.03) 0.95 (0.87–1.04) 0.70 (0.44–0.94) 0.72 (0.51–0.94)
Kappa (95 % confidence interval), Cons. is the consensus evaluation
Observers A, D, and E (in italics) had little experience, B, F, and H had 1–2 years of experience and C and G had more than 3 years of experience
Table 5 Cohen’s linear weighted kappa values for pair-wise comparison of observers for “qualitative” evaluation
Observer A B C D E F G H
B 0.57 (0.37–0.78)
C 0.71 (0.55–0.87) 0.74 (0.55–0.92)
D 0.52 (0.31–0.73) 0.66 (0.43–0.88) 0.66 (0.45–0.86)
E 0.67 (0.45–0.89) 0.63 (0.39–0.87) 0.76 (0.56–0.97) 0.69 (0.48–0.89)
F 0.68 (0.50–0.86) 0.50 (0.27–0.73) 0.64 (0.45–0.83) 0.51 (0.28–0.74) 0.67 (0.46–0.88)
G 0.54 (0.29–0.78) 0.76 (0.56–0.97) 0.57 (0.33–0.82) 0.75 (0.58–0.93) 0.66 (0.42–0.90) 0.53 (0.29–0.78)
H 0.65 (0.46–0.84) 0.74 (0.59–0.90) 0.68 (0.49–0.87) 0.61 (0.40–0.81) 0.64 (0.43–0.86) 0.52 (0.30–0.73) 0.64 (0.45–0.84)
Cons. 0.80 (0.66–0.95) 0.76 (0.58–0.95) 0.90 (0.79–1.01) 0.69 (0.48–0.89) 0.86 (0.68–1.05) 0.74 (0.57–0.91) 0.66 (0.42–0.90) 0.71 (0.52–0.90)
Kappa (95 % confidence interval), Cons. is the consensus evaluation
Observers A, D, and E (in italics) had little experience, B, F, and H had 1–2 years of experience and C and G had more than 3 years of experience
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Comparing with reported inter-observer agreement
among CT measurements [7–9], the observed strong
agreement when using PERCIST 1.0 would indicate that
this method is in fact a helpful tool for evaluating re-
sponse using F-18-FDG PET/CT; i.e., the combination
of a semi-quantitative parameter with an overall visual
evaluation, can provide acceptable agreement among
even rather inexperienced observers. There is still room
for improvement though, and when introducing this
method into our daily routine, we intend to include a
consensus reading between at least two evaluators. The
moderate agreement seen in liver SULmean values is
expected to improve with new versions of software auto-
matically placing and defining liver VOI’s as according
to PERCIST guidelines, which have been introduced as
of late.
This study is limited by the lack of follow-up data. Pre-
viously, we have shown in a smaller study [41] that using
PERCIST for response evaluation in a similar group of
patients predicts survival after 2–4 cycles of chemother-
apy. However, further studies are needed in order to
evaluate which of the two approaches provides the most
relevant clinical information.
Conclusions
SUV (in this case SULpeak) is a robust parameter when
considering inter-observer variability. For a large group
of observers, with varying levels of experience, we have
shown that the semi-quantitative approach of PERCIST
1.0 provides a significant higher overall agreement
among observers than a more qualitative approach when
categorizing the response in NSCLC patients early
during treatment. The inter-observer agreement is
strong when using PERCIST 1.0 even when the level of
instruction is purposely kept to a minimum in order to
mimic the everyday clinical situation; it is thus a very
robust method, ready for routine use. The variability is
largely owing to the subjective elements in the semi-
quantitative method.
The dataset supporting the conclusions of this article
is included as Additional files 1 and 2.
Fig. 6 Observers agreement with the consensus categorization for qualitative end PERCIST evaluation. Red is “multiple level disagreement”
defined as more than one response category difference between the observer and the consensus categorization. Yellow is “single level
disagreement” defined as only one response category difference. Green is full agreement between observer and the consensus categorization
Table 6 Cohen’s linear weighted kappa values for comparison
of the qualitative method and PERCIST 1.0
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Fledelius et al. EJNMMI Research  (2016) 6:71 Page 8 of 10
Additional files
Additional file 1: Figure S7. Agreement in liver SULmean at baseline
among eight observers. Figure S8. Agreement in minimal SULpeak
calculation at baseline among eight observers. (DOCX 567 kb)
Additional file 2: All observers reported data. (XLSX 43 kb)
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